PODD · Insulet Corporation
$149.01
+0.60% last session
End-of-day data · close of 2026-10-23
Market cap
$10B
Enterprise value
$11B
Trailing P/E
27.9
Forward P/E
19.3
Dividend yield
0.0%
Beta
1.10
Avg volume
2M
Employees
5K
Daily Change %
0.60%
5 Days Change
4.98%
10 Days Change
7.23%
30 Days Change
8.52%
60 Days Change
1.86%
Month to Day Change
13.25%
Year to Day Change
-47.89%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PODD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
Jefferies
Buy$190
+27.5% vs priceBarclays
Equal-Weight$150
+0.7% vs priceUBS
Neutral$150
+0.7% vs priceRBC Capital
Outperform$160
+7.4% vs priceWells Fargo
Equal-Weight$144
-3.4% vs priceJP Morgan
Neutral$152
+2.0% vs priceCitigroup
Neutral$172
+15.4% vs priceDeutsche Bank
Buy$190
+27.5% vs priceBank of America
Buy$208
+39.6% vs priceGoldman Sachs
Buy$277
+85.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | Maintains | Buy | $275 → $190 |
| 2026-10-07 | Barclays | Initiates | Equal-Weight | $0.00 → $150 |
| 2026-08-06 | Canaccord Genuity | Maintains | Buy | $249 → $179 |
| 2026-08-06 | Leerink Partners | Downgrade | Outperform → Market Perform | $247 → $145 |
| 2026-08-06 | TD Cowen | Maintains | Hold | $294 → $144 |
| 2026-08-06 | UBS | Maintains | Neutral | $174 → $150 |
| 2026-08-06 | RBC Capital | Maintains | Outperform | $245 → $160 |
| 2026-08-06 | Bernstein | Maintains | Outperform | $200 → $175 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 66 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 6.1% above the 50-day MA ($140.50).
- bearish: Price vs 200-day MA: Trading 18.2% below the 200-day MA ($182.16).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.77) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($130.47) and high ($346.36).
PODD Price Chart
Loading chart for PODD…
Fundamentals
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.